Rosenthal & Rosenthal announced the completion of a recent $25 million recourse factoring deal for a private equity-owned pharmaceutical and healthcare products company.
 
The company is focused on developing drug-device combination products in the healthcare sector and was looking to secure a new alternative financing facility to support its seasonal needs. The opportunity was referred to Rosenthal by one of our long-time Bank partners, as the company was exploring traditional asset based lending facilities with banks.
 
Rosenthal stepped in to provide a $25 million recourse factoring facility that was uniquely structured to include multiple A/R advance rates and more flexible criteria for customer terms.
 
“Our ability to quickly assess the opportunity and meet the client’s aggressive timeline for closing in weeks—not months—made Rosenthal uniquely positioned to assist on this deal,” said Leigh Lones, Rosenthal’s Head of Recourse Factoring division. “This transaction is a great example of how effective recourse factoring can be for companies like this, with quick, simple pricing and a flexible structure that’s aligned to address a client’s specific needs. We’re pleased to have robust and productive working relationships with our referral banks and look forward to assisting on similar transactions in the future.”
 
Rosenthal & Rosenthal is the leading factoring, asset based lending, purchase order financing, d2c and e-commerce inventory financing firm in the United States. Founded in 1938 by Imre J. Rosenthal, the firm is now led by the third generation of the Rosenthal family. As a privately held company, Rosenthal is committed to providing personalized service and flexible lending to clients across a broad range of industries. Rosenthal has offices in New York, California, Georgia and North Carolina.